Jonathan Kearsey
Fundador en Leads To Development .
Perfil
Jonathan Kearsey is the founder of Leads To Development.
He currently works as a Preclinical Manager at APIM Therapeutics AS.
Previously, he worked as a Research Director at Diatos SA and Exonhit.
He holds a doctorate degree from the University of London.
Cargos activos de Jonathan Kearsey
| Empresas | Cargo | Inicio |
|---|---|---|
APIM Therapeutics AS
 APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Corporate Officer/Principal | - |
| Leads To Development | Fundador | - |
Antiguos cargos conocidos de Jonathan Kearsey.
| Empresas | Cargo | Fin |
|---|---|---|
Diatos SA
 Diatos SA Pharmaceuticals: MajorHealth Technology Diatos SA develops innovative therapies for the treatment of cancer. The firm leverages its peptide-based, intracellular drug delivery & tumor targeting technologies to improve the properties of existing therapeutics. Its products include DaunoXome, DTS-301 and DTS-108. The company was founded in 1999 and headquartered in Paris, France. | Director Técnico/Científico/I+D | 15/09/2009 |
Exonhit
 Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Director Técnico/Científico/I+D | - |
Formación de Jonathan Kearsey.
| University of London | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
Diatos SA
Diatos SA Pharmaceuticals: MajorHealth Technology Diatos SA develops innovative therapies for the treatment of cancer. The firm leverages its peptide-based, intracellular drug delivery & tumor targeting technologies to improve the properties of existing therapeutics. Its products include DaunoXome, DTS-301 and DTS-108. The company was founded in 1999 and headquartered in Paris, France. | Health Technology |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Health Technology |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
| Leads To Development |
- Bolsa de valores
- Insiders
- Jonathan Kearsey
